KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation

Anneloes L. Noordhof; Oke Dimas Asmara; Kim de Jong; Rolof GP Gijtenbeek; Ymkje MA Huitema; F Van Vollenhoven; Ben J.W. Venmans; Lizza Hendriks; Wouter Heero van Geffen

doi:10.1002/14651858.cd016054

February 17, 2026Cochrane library

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effectiveness and safety of G12C inhibitors against chemotherapy in advanced non-small cell lung cancer with a KRAS mutation.
Conduct a Cochrane Review.
Compare G12C inhibitors and chemotherapy.
Focus on adults with advanced/metastatic NSCLC harboring the KRAS G12C mutation.
Evaluate potential benefits and harms of G12C inhibitors over chemotherapy.
Identify specific outcomes in the treatment of advanced NSCLC.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

A Cochrane Review assesses G12C-inhibitors' effects versus chemotherapy in adults with advanced NSCLC, suggesting potential benefits.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of G12C-inhibitors compared to chemotherapy in second line and beyond in adults with advanced/metastatic non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma (KRAS) G12C mutation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Noordhof et al. (2026) studied this question.

synapsesocial.com/papers/6997f984ad1d9b11b3452489 https://doi.org/10.1002/14651858.cd016054

View at Publisher

Ask AI

Bookmark

Share

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading